FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B Alnylam Pharmaceuticals Press Release | Mar 28, 2025

#Alnylam gets another #RNAiTherapeutic approved, this time in hemophilia (A and B) targeting anti-thrombin. Sanofi has majority rights to it.

This one was a hard slog. Commercial uptake of this prophylactic once-every-2-month subQ will be interesting.

investors.alnylam.com/press-releas...